A Study to Assess the Time to Onset of Action of Staccato Alprazolam Versus Midazolam and Diazepam in Healthy Participants
Completed · Phase 1 · NCT07020988
Conditions: Healthy Participants
At a glance
- Research payments reported, 2025
- $247
- U.S. investigators named
- 0
- Sites paid
- 1
- Planned or actual enrollment
- 55
About the trial
- Sponsor
- UCB Biopharma SRL
- Tested
- Staccato Alprazolam (drug), Midazolam (drug), Diazepam (drug)
- Dates
- Started 2025-06-12; completion 2026-01-21
- Results posted
- Not yet
The purpose of this study is to estimate the difference in the time to onset of action between Staccato alprazolam and intravenous (iv) midazolam using changes in power in the combined spindle and β1 frequency bands in the qEEG (quantitative electroencephalogram).
From ClinicalTrials.gov, last updated 2026-02-20. Full record, eligibility and contacts (opens in a new tab)
Industry funding
UCB SA reported $247 in research payments for this study in 2025 (3 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
Sites paid to run it
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.